Top Markets
#1 Black Phoenix Black Phoenix +825.47%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +24.88%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.87%
#4 Prom Prom +20.14%
#5 SAFEcoin SAFEcoin +19.78%
#6 Magma Finance Magma Finance +19.66%
#7 Beam Beam +19.21%
#8 Bless Bless +17.62%
#9 pipedog pipedog +17.24%
#10 YFSX YFSX +16.01%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Zymeworks Inc. Zymeworks Inc.

Zymeworks Inc.

ZYME
Rank in Stocks #6240
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase,... Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Share Price
$29.18
Market Cap
$2.15B
Change (1 day)
-0.44%
Change (1 year)
95.41%
Country
US
Trade Zymeworks Inc. (ZYME)

Category

Healthcare
Operating Margin for Zymeworks Inc. (ZYME)
Operating Margin as of 2026 TTM: 0.00%
According to Zymeworks Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Zymeworks Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.